What the FDA labels say about taking them together
Benazepril and temsirolimus
Benazepril's FDA label of September 30, 2025 names temsirolimus in its drug interactions section; temsirolimus's label does not name benazepril itself but warns about its class (ACE inhibitors). The benazepril label: “Patients receiving coadministration of ACE inhibitor and mTOR inhibitor therapy or a neprilysin inhibitor may be at increased risk for angioedema.”
Check it at the source: the benazepril FDA label on DailyMed (effective September 30, 2025, Validus Pharmaceuticals LLC); the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the benazepril label say about temsirolimus?
Benazepril label, drug interactionsTarget of Rapamycin (mTOR) Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.
Benazepril label, warnings and precautionsPatients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7) ].
Source: FDA drug label (Lotensin), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e), via openFDA; the full label on DailyMed
What does the temsirolimus label say about benazepril?
Temsirolimus's label does not name benazepril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Benazepril | Temsirolimus | |
|---|---|---|
| Labeled for | High blood pressure | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0789 per tablet 20 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once